PRMT5 Transgenic Mice Develop Aggressive Lymphoblastic Lymphomas

被引：0

作者：

Smith, Porsha L. ^{[1
]}

Yan, Fengting ^{[2
]}

Patton, John T. ^{[1
]}

Alinari, Lapo ^{[3
,4
]}

Karkhanis, Vrajesh ^{[1
]}

Ayers, Leona ^{[5
]}

Muthusamy, Natarajan ^{[6
]}

Mishra, Anjali ^{[7
]}

Ahmed, Elshafa ^{[1
]}

Sif, Said ^{[8
]}

Lapalombella, Rosa ^{[1
]}

Baiocchi, Robert A. ^{[1
]}

机构：

[1] Ohio State Univ, Wexner Med Ctr, Dept Internal Med, Ctr Comprehens Canc,Div Hematol, Columbus, OH USA

[2] Univ Washington Med Ctr, Div Hematol, Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[3] Ohio State Univ, Div Hematol, Dept Internal Med, Ctr Comprehens Canc, Columbus, OH USA

[4] Ohio State Univ, Columbus, OH USA

[5] Ohio State Univ, Dept Pathol, Columbus, OH USA

[6] Ohio State Univ, Div Hematol, Columbus, OH USA

[7] Ohio State Univ, Div Dermatol, Columbus, OH USA

[8] Qatar Univ, Dept Biol & Environm Sci, Coll Arts & Sci, Doha, Qatar

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.2936.2936

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2936

引用

页数：4

共 50 条

[21] Antitumor Effects of PRMT5 Inhibition in Sarcomas
Verbeke, Stephanie
Bourdon, Aurelien
Guegan, Jean-Philippe
Leroy, Laura
Chaire, Vanessa
Richard, Elodie
Bessede, Alban
Italiano, Antoine
CANCER RESEARCH COMMUNICATIONS, 2023, 3 (11): : 2211 - 2220
[22] Identification of PRMT5 as a therapeutic target in cholangiocarcinoma
Elurbide, Jasmin
Colyn, Leticia
Latasa, Maria U.
Uriarte, Iker
Mariani, Stefano
Lopez-Pascual, Amaya
Valbuena, Emiliana
Castello-Uribe, Borja
Arnes-Benito, Robert
Adan-Villaescusa, Elena
Martinez-Perez, Luz A.
Azkargorta, Mikel
Elortza, Felix
Wu, Hanghang
Krawczyk, Marcin
Schneider, Kai Markus
Sangro, Bruno
Aldrighetti, Luca
Ratti, Francesca
Gardini, Andrea Casadei
Marin, Jose J. G.
Amat, Irene
Urman, Jesus M.
Arechederra, Maria
Luz Martinez-Chantar, Maria
Trautwein, Christian
Huch, Meritxell
Javier Cubero, Francisco
Berasain, Carmen
Fernandez-Barrena, Maite G.
Avila, Matias A.
GUT, 2025, 74 (01) : 116 - 127
[23] IDENTIFICATION OF PRMT5 AS A THERAPEUTIC TARGET IN CHOLANGIOCARCINOMA
Elurbide, Jasmin
Colyn, Leticia
Latasa, Maria Ujue
Uriarte, Iker
Mariani, Stefano
Lopez-Pascual, Amaya
Valbuena, Emiliana
Castello-Uribe, Borja
Benito, Robert Arnes
Adan-Villaescusa, Elena
Azkargorta, Mikel
Elortza, Felix
Wu, Hanghang
Krawczyk, Marcin
Schneider, Kai Markus
Sangro, Bruno
Aldrighetti, Luca
Ratti, Francesca
Casadei-Gardini, Andrea
Marin, Jose
Amat, Irene
Urman, Jesus
Arechederra, Maria
Martinez-Chantar, Maria
Trautwein, Christian
Huch, Meritxell
Cubero, Francisco Javier
Berasain, Carmen
Fernandez-Barrena, Maite
Avila, Matias
HEPATOLOGY, 2024, 80
[24] PRMT5: An Emerging Target for Pancreatic Adenocarcinoma
Lee, Michael K. C.
Grimmond, Sean M.
McArthur, Grant A.
Sheppard, Karen E.
CANCERS, 2021, 13 (20)
[25] PRMT5 as a druggable target for glioblastoma therapy
Banasavadi-Siddegowda, Yeshavanth Kumar
Welker, Alessandra M.
An, Min
Yang, Xiaozhi
Zhou, Wei
Shi, Guqin
Imitola, Jaime
Li, Chenglong
Hsu, Sigmund
Wang, Jiang
Phelps, Mitch
Zhang, Jianying
Beattie, Christine E.
Baiocchi, Robert
Kaur, Balveen
NEURO-ONCOLOGY, 2018, 20 (06) : 753 - 763
[26] Identification of PRMT5 as a therapeutic target in cholangiocarcinoma
Elurbide, Jasmin
Colyn, Leticia
Latasa, Maria U.
Uriarte, Iker
Mariani, Stefano
Lopez-Pascual, Amaya
Valbuena, Emiliana
Castello-Uribe, Borja
Arnes-Benito, Robert
Adan-Villaescusa, Elena
Martinez-Perez, Luz A.
Azkargorta, Mikel
Elortza, Felix
Wu, Hanghang
Krawczyk, Marcin
Schneider, Kai Markus
Sangro, Bruno
Aldrighetti, Luca
Ratti, Francesca
Casadei Gardini, Andrea
Marin, Jose J. G.
Amat, Irene
Urman, Jesus M.
Arechederra, Maria
Martinez-Chantar, Maria Luz
Trautwein, Christian
Huch, Meritxell
Cubero, Francisco Javier
Berasain, Carmen
Fernandez-Barrena, Maite
Avila, Matias A.
GUT, 2024, 74 (01)
[27] PRMT5 is a therapeutic target in choroidal neovascularization
Anbukkarasi Muniyandi
Matthew Martin
Kamakshi Sishtla
Aishat Motolani
Mengyao Sun
Nathan R. Jensen
Xiaoping Qi
Michael E. Boulton
Lakshmi Prabhu
Tao Lu
Timothy W. Corson
Scientific Reports, 13
[28] The Structure and Functions of PRMT5 in Human Diseases
Motolani, Aishat
Martin, Matthew
Sun, Mengyao
Lu, Tao
LIFE-BASEL, 2021, 11 (10):
[29] PRMT5 inhibitors as novel treatment for cancers
Falk, Hendrik
Foitzik, Richard C.
Allan, Elizabeth
deSilva, Melanie
Yang, Hong
Bozikis, Ylva E.
Nikac, Marica
Walker, Scott R.
Camerino, Michelle A.
Morrow, Ben J.
Stupple, Alexandra E.
Lagiakos, Rachel
Pinson, Jo-Anne
Lessene, Romina
Kersten, Wilhelmus J. A.
Ganame, Danny G.
Holmes, Ian P.
Lunniss, Gill E.
Chung, Matthew
Hermans, Stefan J.
Parker, Michael W.
Thistlethwaite, Alison
White, Karen
Charman, Susan A.
Monahan, Brendon J.
Pilling, Patricia
Grusovin, Julian
Peat, Thomas S.
Sonderegger, Stefan
Toulmin, Emma
Jane, Stephen M.
Curtis, David J.
Stupple, Paul A.
Street, Ian P.
CANCER RESEARCH, 2015, 75
[30] Acetylation regulates the oncogenic functions of PRMT5
Vo, Tam Thuy Lu
Do, Yen Thi
Pham, Thi Tuyet Mai
Shin, So-Jin
Kim, Jin Young
Lee, Seungmee
Ha, Eunyoung
Seo, Ji Hae
CANCER RESEARCH, 2023, 83 (07)

← 1 2 3 4 5 →